The old drug discovery system was built to benefit shareholders, not patients. But a new, Linux-like platform could transform the way medicine is developed—and energize the race against COVID-19. At the end of March, I was supposed to attend a dinner party where the core topic of discussion was how online collaboration could tackle diseases that are traditionally ignored by Big Pharma. Instead of wine and good food, experts from the National Institutes of Health, Harvard University, Takeda Pharmaceutical, and I were forced to settle in at our home offices and dial into Zoom. In some ways, it was the perfect format to discuss how open-source tools could help find new cures. Read Full Story
More